BASF and Catalent join forces to solve bioavailability challenges

10-Apr-2012 - USA

Catalent Pharma Solutions and BASF have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges.

The companies aim to combine their expertise to provide pharmaceutical customers with a unique range of seamless solutions to address pipeline challenges with a large majority of BCS Class II and IV poorly bioavailable compounds. From feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services, excipients and optimal dose form development, to scale-up and supply, BASF and Catalent provide a full solution to one of the most important pipeline challenges in the industry – getting better treatments to market faster.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...